3M Aims For Acelity In $6.7Bn Deal To Expand Wound-Care Presence

3M is betting big on wound-care maker Acelity and paying $6.7bn to buy the company and its KCI subsidiaries in its largest acquisition to date. 

Merging Business Network-Business leaders in global agreement
• Source: Shutterstock

Industrial conglomerate 3M Co. is paying $6.7bn to buy Acelity LP Inc. and its KCI subsidiaries in an ambitious move to expand its presence in the wound-care market. 

San Antonio, TX-based Acelity, a maker of advanced wound-care products, generated $1.5bn in revenue last year, with about 75% of sales in the Americas. 3M will acquire the company from a consortium of funds advised by Apax Partners and affiliates of Canada Pension Plan Investment Board (CPPIB) and the Public Sector Pension Investment Board (PSP Investments) with cash along with proceeds from the issuance of new debt

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Wound Management

Amferia Aims To Bring Peptide Hydrogel To Fight Against Antimicrobial Resistance

 

Amferia is developing an antimicrobial peptide hydrogel dressing to combat infections in acute wounds in humans and veterinary contexts. Supported by €1.2m of new venture capital financing, the company is planning pivotal clinical studies to support an FDA application later this year and CE mark submission in 2026-2027.

Cresilon’s FDA-Cleared Traumagel Stops Severe Bleeding Instantly, Available In US In Late 2024

 
• By 

Cresilon CEO Joe Landolina says the newly FDA-cleared Traumagel for moderate and severe bleeding is easier to use than many currently available solutions like gauzes and sponges, and provides faster results.

Podcast: AMR, UTI, Breathomics And 3D Printing Technology Innovators Profiled At BioWales 2024

 
• By 

Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024. Hear from CEO John McKinley on Imspex Diagnostics' plans in embedded podcast.  

Podcast: AMR, UTI, Breathomics And 3D Printing Technology Innovators Profiled At BioWales 2024

 
• By 

Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024.

More from Device Area

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.

First At-Home Cervical Cancer Screening Tool Gets FDA Clearance

 
• By 

The US FDA has approved the Teal Wand, the first at-home cervical cancer screening device. Capable of detecting preclinical cancer with 96% accuracy, it will launch in California in June and expand nationwide soon after.

SS Innovations Files For De Novo For SSi Mantra 3 Surgical Robotic System For Multispecialty Indications

 
• By 

SS Innovations announced plans to file a de novo application with the US FDA for its SSi Mantra 3 surgical robot, already approved for marketing in six countries. The Florida-based firm also plans to pursue the CE mark for European commercialization.